




Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug launch.
Checkpoint is a commercial-stage company that develops novel treatments for patients with solid tumor cancers, and the acquisition includes UNLOXCYT, an FDA-approved treatment for advanced skin cancer.
Analysts said despite Shanghvi’s exit, there are a slew of reasons to be bullish on Suzlon.
Shanghvi said that the company’s businesses are well-positioned, and it expects high-single-digit consolidated topline growth for FY24
The Sun Pharma founder says it for his children, Aalok and Vidhi, to decide if they want to be owner-managers, working managers or adopt a hands-off approach